EUCTR2004-001162-40-IT进行中（未招募）不适用
An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.
EISAI LTD UK0 个研究点开始时间: 2005年9月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASICerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.MedDRA version: 7.0 Level: PT Classification code 10057678EUCTR2004-001162-40-GBEisai Ltd150
进行中（未招募）
1 期
An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIEUCTR2004-001162-40-ESEisai Ltd150
进行中（未招募）
不适用
An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASICerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.MedDRA version: 7.0Level: PTClassification code 10057678EUCTR2004-001162-40-DEEisai Ltd150
进行中（未招募）
1 期
An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIEUCTR2004-001162-40-FIEisai Ltd150
进行中（未招募）
不适用
An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASICerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.MedDRA version: 7.0Level: PTClassification code 10057678EUCTR2004-001162-40-SEEisai Ltd150